Is Atara Biotherapeutics, Inc. (ATRA) a Buy, Sell, or Hold?
NASDAQ : ATRA
Atara Biotherapeutics, Inc.
$8.94 USD
$0.33 (3.83%)
- Volume
- 29.23K
- Average Volume
- 1.43M
- Market Capitalization
- $80.55M
- P/E Ratio
- -13.55
- Dividend Yield
- 0.00%
- Price Target
- $13.00
- Year High
- $19.15
- Year Low
- $3.92
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.16
Company Overview
NASDAQ
Anhco Nguyen
Biotechnology
Healthcare
ATRA
13
US
USD
Liquidity Metrics
-0.27
2.16
2.16
1.48
0.00
Sales & Valuation
$120.77M
3.48
-3.37
-3.11
-1.84
Profitability
$2.57
$32.69M
-40.91%
-40.78%
25.68%
-47.34%
P/E Metrics
-13.55
0.03
0.03
Analyst Price Target & Rating
$13.00
$13.00
$13.00
2/5
13 Analysts
-31.23%
Financial Health Scores
-140.46
1/9
$6.53M
$20M
$57.31M
-$5.83M
Key Metrics (TTM)
$79.31M
3.43
-14.47
2.16
25.68%
-41.06%
-7.81%
-33.35%
-259 days
Company Executives
| Name | Title |
|---|---|
| John Chao | Head of Legal |
| Alex Chapman | Vice President of Corporate Communications & Investor Relations |
| Anhco Nguyen | President, Chief Executive Officer & Director |
| Jim Sesic | Senior Vice President of Regulatory Affairs |
| Yanina Grant-Huerta | Chief Accounting Officer & Principal Accounting Officer |
| Kevin G. Sarney | Interim Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA24 ... 31 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
Atara Biotherapeutics Announces Changes to Its Board of Directors
2026-06-12 16:00:00
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors. “On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its share.
2026-06-11 06:52:00
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient has been dosed in QUATRO-APL, the company's global Phase 3 clinical trial evaluating QTX-2101, an investigational oral capsule formulation of arsenic trioxide, in combination with all-trans retinoic acid (ATRA), for the treatment of patients with newly diagnosed, low-risk Acute Promyelocytic Leukemia, or APL.
2026-05-26 09:00:00
NEW YORK, May 26, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA). Shareholders who purchased shares of ATRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
2026-05-22 15:00:00
Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics
2026-05-22 14:41:00
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026. Atara describes itself as a company that “develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United Kingdom.”For more information, submit a form, email attorney Phillip Kim, or give us.
2026-05-22 12:00:00
New York, New York--(Newsfile Corp. - May 22, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. (NASDAQ: ATRA) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Atara securities between May 20, 2024 and January 9, 2026, both dates inclusive (the "Class Period").
2026-05-22 12:00:00
LOS ANGELES, May 22, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). IF YOU SUFFERED A LOSS ON YOUR ATARA BIOTHERAPEUTICS INVESTMENTS, CLICK HERE BEFORE MAY 22, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
2026-05-22 10:32:00
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026, inclusive (the “Class Period”), of the important May 22, 2026 lead plaintiff deadline.
Frequently Asked Questions
-
What is the current Atara Biotherapeutics, Inc. (ATRA) stock price?
-
Atara Biotherapeutics, Inc.(NASDAQ:ATRA) stock price is $8.94 in the last trading session. During the trading session, ATRA stock reached the peak price of $19.145 while $3.92 was the lowest point it dropped to. The percentage change in ATRA stock occurred in the recent session was 3.83% while the dollar amount for the price change in ATRA stock was $0.33.
-
ATRA's industry and sector of operation?
-
The NASDAQ listed ATRA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ATRA?
-
John Chao | Head of Legal
Alex Chapman | Vice President of Corporate Communications & Investor Relations
Anhco Nguyen | President, Chief Executive Officer & Director
Jim Sesic | Senior Vice President of Regulatory Affairs
Yanina Grant-Huerta | Chief Accounting Officer & Principal Accounting Officer -
How many employees does ATRA have?
-
Number of ATRA employees currently stands at 13. ATRA operates from 1280 Rancho Conejo Blvd, Thousand Oaks, CA 91320, US.
-
Link for ATRA official website?
-
Official Website of ATRA is: https://www.atarabio.com
-
How do I contact ATRA?
-
ATRA could be contacted at phone #650 278 8930 and can also be accessed through its website. ATRA operates from 1280 Rancho Conejo Blvd, Thousand Oaks, CA 91320, US.
-
How many shares of ATRA are traded daily?
-
The average number of ATRA shares traded daily for last 3 months was 1.43M.
-
What is the market cap of ATRA currently?
-
The market value of ATRA currently stands at $80.55M with its latest stock price at $8.94